Publications

Publications

We invite you to explore Bayer-supported publications. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

To help narrow down your search, choose the relevant tags and click Apply. Selecting multiple tags will narrow your results.

Last updated March 2025.

IPPI: Immediate Postpartum Insertion

SD: Sleep Disturbances

PK: Pharmacokinetics

IUD: Intrauterine Device

VMS: Vasomotor Symptoms

Types of Enhancements Available

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 25    

Filtered results: 25

Population characteristics of intrauterine device users in real-world clinical practice across Europe - insights from the EURAS-LCS12 study

Eggebrecht L, Bauerfeind A, Boehnke T, Rizzo M, Hagemann C, Lange J, Viet M, Pauls K, von Stockum S, Klinghardt M, Heinemann K. Contracept Reprod Med.

Eggebrecht L., Bauerfeind A. Boehnke T., Rizzo M., Hagemann C., ,

Consensus recommendations for measuring the impact of contraception on the menstrual cycle in contraceptive clinical trials

Mackenzie ACL, et al. Contraception. Jan 2025; Online ahead of print.

Mackenzie A.C.L., Chung S., Hoppes E., Miller N., Burke A.E., Ac,

Population pharmacokinetic-pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data

Willmann S, et al. CPT Pharmacometrics Syst Pharmacol. July 2024;00:1-13.

Willmann S, Lloyd A, Austin R, Joseph S, Solms A, Zhang Y, Schne,

Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials

Pinkerton J, et al. JAMA. Aug 2024; Online Ahead of Print.

Pinkerton J,

Real-world evaluation of treatment utilization by women experiencing vasomotor symptoms associated with menopause in the United States and Europe: Findings from the REALISE study.

Kingsberg S, et al. Maturitas. Aug 2024; 22(189):108096.

Kingsberg A,

Treatment utilization and non-drug interventions for vasomotor symptoms in breast cancer survivors taking endocrine therapy: Real-world findings from the United States and Europe

Kingsberg S, et al. Maturitas. 2024 Jul; 23:188:108071.

Kingsberg S,

Real-world clinical evaluation of natural and induced vasomotor symptoms in the USA and Europe

Kingsberg S, et al. Climacteric. May 2024; 2:1-9.

Kingsberg S,

Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause

Pinkerton J, et al. Menopause. Apr 2024; 10-97.

Pinkerton J,

Global view of vasomotor symptoms and sleep disturbance in menopause: a systematic review

Kingsberg SA, et al. Climacteric. 2023 Dec; 26(6):537-549.

Kingsberg,

Risks of Uterine Perforation and Expulsion Associated With Intrauterine Devices

Fassett MJ, et al. Obstet Gynecol. Sep 2023; 142(3):641-651.

Fassett MJ,